Third-generation NA (ETV, TDF and TAF) are drugs with a high barrier to HBV resistance and high efficacy in controlling viral replication (HBV DNA) and inflammatory activity (ALT level). Therefore, first-line NA have demonstrated a high efficacy achieving virological and biochemical response in adherent patients, but HBsAg seroclearance is anecdotic (Table 2).32,33Table 2 Efficacy of Approved First-Line Antiviral Therapies in Chronic Hepatitis B Adults. Not Head-to Head Comparisons, and Different Follow-Up